- Leap Therapeutics Inc (NASDAQ:LPTX) has agreed to acquire Flame Biosciences Inc, a privately-held biotechnology company, in an all-stock transaction.
- The deal adds Flame’s assets, including FL-301, its clinical stage anti-Claudin18.2 monoclonal antibody; FL-302, its preclinical anti-Claudin18.2/CD137 bispecific monoclonal antibody; and FL-501, its preclinical anti-GDF15 monoclonal antibody.
- Flame ended the December quarter with net cash of approximately $50 million.
- Leap Therapeutics’ total cash balance of the combined company as of December 31, 2022, was approximately $115 million, expected to be sufficient to fund Leap’s planned operating expenses and development plans to mid-2025.
- Leap will issue approximately 19.8 million shares and approximately 136,833 shares of a newly designated Series X non-voting convertible preferred stock to Flame stockholders.
- In addition, Leap will pay the Flame shareholders 80% of the after-tax net proceeds, if any, from certain post-merger transactions to out-license or sell FL-101 or FL-103, Flame’s anti-IL-1b antibodies.
- Leap has added two members nominated by Flame to its existing eight-person Board of Directors.
- Price Action: LPTX shares are down 2.18% at $0.57 during the premarket session on the last check Tuesday.
- Photo Via Company
Tier One MSOs Gain Most On SAFE Act Reintroduction
The latest version of the SAFE Banking Act was introduced to the Senate and House on April 26th. In a cannabis market dying for any source of optimism, the introduction sparked initial sharp increases in stock prices. Some gains drifted away by Friday, partially due to Senator Schumer’s pledge to add social justice provisions to the bill.
